• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by bluebird bio Inc.

    6/2/25 10:25:51 AM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLUE alert in real time by email
    S-8 POS 1 d94420ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on June 2, 2025

    Registration No. 333-189560

    Registration No. 333-283235

    Registration No. 333-272714

    Registration No. 333-194340

    Registration No. 333-202283

    Registration No. 333-209715

    Registration No. 333-216179

    Registration No. 333-223132

    Registration No. 333-229768

    Registration No. 333-236490

    Registration No. 333-253398

    Registration No. 333-270922

    Registration No. 333-257135

    Registration No. 333-263310

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-189560

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-283235

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-272714

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194340

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-202283

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-209715

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-216179

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-223132

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-229768

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-236490

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-253398

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270922

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-257135

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-263310

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    bluebird bio, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   13-3680878

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    455 Grand Union Boulevard

    Somerville, MA 02145

    (339) 499-9300

    (Address of Principal Executive Offices) (Zip Code)

     

     

    SECOND AMENDED AND RESTATED 2002 EMPLOYEE, DIRECTOR AND CONSULTANT PLAN

    2010 STOCK OPTION AND GRANT PLAN

    2013 EMPLOYEE STOCK PURCHASE PLAN

    2013 STOCK OPTION AND INCENTIVE PLAN

    2021 INDUCEMENT PLAN

    AMENDED AND RESTATED 2023 INCENTIVE AWARD PLAN

    2023 INCENTIVE AWARD PLAN

    (Full titles of the plans)

    David Meek

    President

    bluebird bio, Inc.

    455 Grand Union Boulevard

    Somerville, MA 02145

    (339) 499-9300

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Mark A. Stagliano, Esq.

    Wachtell, Lipton, Rosen & Katz

    51 West 52nd Street

    New York, New York 10019

    (212) 403-1000

     

    Gregg Griner, Esq.

    Albert Vanderlaan, Esq.

    Orrick, Herrington & Sutcliffe LLP

    222 Berkeley St., Suite 2000

    Boston, MA 02116

    (617) 880-2212

     

    Matthew S. Arenson, P.C.

    Kirkland & Ellis LLP

    98 SE 7th St, Suite 700

    Miami, FL 33131

    (305) 432-5600

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”), filed by bluebird bio, Inc., a Delaware corporation (the “Company”), remove from registration all shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”) previously registered under the following Registration Statements on Form S-8 filed by the Company (the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”) pertaining to the registration of shares of Common Stock.

     

      •  

    Registration No. 333-189560, which was previously filed with the SEC on June 24, 2013, registering 280,220 shares of Common Stock under the Second Amended and Restated 2002 Employee, Director and Consultant Plan, 3,620,296 shares of Common Stock under the 2010 Stock Option and Grant Plan, 955,000 shares of Common Stock under the 2013 Stock Option and Incentive Plan and 238,000 shares of Common Stock under the 2013 Employee Stock Purchase Plan;

     

      •  

    Registration No. 333-283235, which was previously filed with the SEC on November 14, 2024, registering 15,000,000 shares of Common Stock under the Amended and Restated 2023 Incentive Award Plan;

     

      •  

    Registration No. 333-272714, which was previously filed with the SEC on June 16, 2023, registering 5,200,000 shares of Common Stock under the 2023 Incentive Award Plan;

     

      •  

    Registration No. 333-194340, which was previously filed with the SEC on March 5, 2014, registering 960,320 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-202283, which was previously filed with the SEC on February 25, 2015, registering 1,293,592 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-209715, which was previously filed with the SEC on February 25, 2016, registering 1,475,755 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-216179, which was previously filed with the SEC on February 22, 2017, registering 1,627,676 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-223132, which was previously filed with the SEC on February 21, 2018, registering 1,976,240 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-229768, which was previously filed with the SEC on February 21, 2019, registering 2,189,530 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-236490, which was previously filed with the SEC on February 18, 2020, registering 2,214,719 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-253398, which was previously filed with the SEC on February 23, 2021, registering 2,657,263 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-270922, which was previously filed with the SEC on March 29, 2023, registering 3,316,932 shares of Common Stock under the 2013 Stock Option and Incentive Plan;

     

      •  

    Registration No. 333-257135, which was previously filed with the SEC on June 15, 2021, registering 1,400,000 shares of Common Stock under the 2013 Employee Stock Purchase Plan and 600,000 shares of Common Stock under the 2021 Inducement Plan; and


      •  

    Registration No. 333-263310, which was previously filed with the SEC on March 4, 2022, registering 2,844,617 shares of Common Stock under the 2013 Stock Option and Incentive Plan and 650,000 shares of Common Stock under the 2021 Inducement Plan.

    On February 21, 2025, the Company entered into an Agreement and Plan of Merger (as amended from time to time, the “Merger Agreement”) with Beacon Parent Holdings, L.P., a Delaware limited partnership (“Parent”) and Beacon Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”). On June 2, 2025, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving as an indirect wholly owned subsidiary of Parent (the “Merger”).

    As a result of the Merger, the Company has terminated all offerings of the Company’s securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all plan interests and any and all securities registered for issuance under the Registration Statements that remain unsold as of the date hereof. This filing is made in accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance that remain unsold at the termination of the offering.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Somerville, State of Massachusetts on June 2, 2025.

     

    BLUEBIRD BIO, INC.
    By:   /s/ David Meek
      Name: David Meek
      Title: President

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $BLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUE

    DatePrice TargetRatingAnalyst
    2/24/2025Underweight → Neutral
    Analyst
    2/24/2025$29.00Overweight
    Analyst
    11/18/2024Neutral → Underweight
    Analyst
    11/15/2024Neutral → Underweight
    JP Morgan
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    8/15/2024Overweight → Neutral
    JP Morgan
    12/11/2023Hold → Reduce
    HSBC Securities
    12/8/2023$3.00 → $7.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

      New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer

      6/2/25 8:34:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer

      All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") for either (x) $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right ("CVR") if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December

      5/30/25 8:30:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Additionally, the Company today announced that Ayrmid Ltd. ("Ayrmid") has confirmed it will not submit a binding proposal to acquire bluebird following bluebird's amended agreement with Carlyle and SK Capital. The bluebird Board of Directors

      5/27/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

      CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th

      6/2/24 10:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Appoints O. James Sterling as Chief Financial Officer

      bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi

      5/29/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business & Legal Officer Vittiglio Joseph returned 5,625 shares to the company and was granted 2,500 shares, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 6:02:16 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Agwunobi John O returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:46:09 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Vachon Mark returned 1,245 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      6/3/25 5:38:38 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    SEC Filings

    See more
    • SEC Form EFFECT filed by bluebird bio Inc.

      EFFECT - bluebird bio, Inc. (0001293971) (Filer)

      6/4/25 12:15:02 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by bluebird bio Inc.

      POS AM - bluebird bio, Inc. (0001293971) (Filer)

      6/2/25 10:37:46 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by bluebird bio Inc.

      S-8 POS - bluebird bio, Inc. (0001293971) (Filer)

      6/2/25 10:34:44 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Analyst initiated coverage on Bluebirdbio with a new price target

      Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

      2/24/25 7:04:33 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bluebirdbio downgraded by Analyst

      Analyst downgraded Bluebirdbio from Neutral to Underweight

      11/18/24 4:13:05 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Financials

    Live finance-specific insights

    See more
    • bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

      - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

      11/14/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

      11/6/24 4:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

      Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar

      9/24/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care